Thank you, Jennifer. Good morning, and thank you to everyone for joining us on the call. As seen on Slide 15, total revenue for the fourth quarter of 2023 of $20.5 million grew by 77% year-over-year, bringing 2023 annual revenue to $62.6 million, a 68% improvement over 2022. While we were disappointed by the performance of our CarbonSmart business during the quarter, revenue from our core Biorefining Carbon Capture and Utilization business grew 103% year-on-year in the fourth quarter to $14.2 million, driven mainly by ongoing and recently initiated engineering services work across several projects. The Biorefining business saw 101% growth year-on-year in 2023, reaching $42.6 million. JDA & Contract Research revenue grew 21% year-on-year in 2023, reaching $14.6 million. This performance was supported by several customers and government grants which are typically multi-year in duration. On the CarbonSmart side, while this part of the business significantly underperformed our expectations for the reasons we have discussed, especially in the fourth quarter, for the full year our CarbonSmart business achieved 33% growth year-on-year, reaching $5.3 million. Our focus on revenue quality continued in the fourth quarter as we saw a gross profit improvement of 62% quarter-on-quarter, $8.5 million, bringing the full year gross profit to $17.7 million, approximately doubling our gross profit from the prior year. This fourth quarter improvement was driven by high margin engineering services work in JDA & Contract Research, resulting in fourth quarter gross margins of 41% and full year 2023 gross margin of 28%, up approximately 400 basis points over 2022. While some of this engineering services work in the fourth quarter benefited from extraordinary pricing terms, we do expect gross margin to be in the mid to high 20s for 2024, based on our anticipated revenue mix and significant amount of lower margin equipment revenue in this particular year. We remain focused on improving gross margins while accelerating revenue growth in 2024. Operating expenses continue to decline quarter-on-quarter in the fourth quarter, coming in at $27.1 million. This decline came as a result of lower quarterly research and development and SG&A expenses and greater billable utilization of our teams. Operating expense for 2023 was $124 million, and as a result of the executive reorganization, headcount reductions, and other cost-cutting initiatives Jennifer laid out earlier, we expect 2024 operating expenses will be flat or lower as compared to 2023. To recap, we expect the earlier discussed reorganization initiatives will reduce annualized operating expenses by approximately $5.3 million, although, of course, not all of that will be realized in 2024, and that there are other efficiencies and cash burn reduction opportunities that we are actively pursuing. CapEx spend during 2023 totaled $8.6 million, 20% lower compared to 2022. Turning to adjusted EBITDA and cash, we reduced our adjusted EBITDA loss quarter-over-quarter by 28% to $13.7 million in the quarter, resulting in a full year adjusted EBITDA loss of $80.1 million in 2023. Our cash burn also declined by approximately 36% to $15.4 million for the quarter as we continue to focus on our path of profitability and getting the cash flow positive. We ended the year with $121.4 million in cash on hand, including cash, restricted cash, and investments. Today, as seen on Slide 16, we're introducing our full year 2024 guidance, which includes total revenue of approximately $90 million to $105 million. At the high end, this reflects growth of approximately 68%, in line with the annual growth we experienced last year. We anticipate that Biorefining revenue growth will come from ongoing and new engineering services revenue as existing projects continue engineering work and advance to the subsequent phases of the development cycle, as well as from the sale of equipment from several projects that we expect to proceed to the construction phase of 2024, some of which were delayed from starting construction in 2023. We also expect incremental ongoing growth in recurring revenue with the additions of the ArcelorMittal and Indian Oil facilities [indiscernible]. We've experienced some timing delays for a subset of projects in the middle of the funnel that we attribute certain macroeconomic factors and elongated decision-making processes at some of our licensee customers. As a result, we have modified our forecasting to take into account these projects taking longer to move from early stage engineering to advanced engineering and from advanced engineering to FID construction start. In 2023, such timing delays with projects anticipated to enter construction push those construction starts and associated equipment revenues into 2024 and beyond. It's important to reiterate that projects are not dropping out of the pipeline. Rather, the tougher macroeconomic and higher inflationary environment leading to changes in steel prices and availability of equipment, combined with a lack of uniform regulatory protocols have elongated the recent project development cycles, which were closely monitored. We anticipate JDA & Contract Research revenue to continue its modest growth, but will selectively deploy our resources on high-margin opportunities and work that we believe will lead to future Biorefining licensing opportunities. On the CarbonSmart side of the business, we anticipate moderate growth this year, but believe there is substantial upside potential for the business as we negotiate committed offtake supply with our partners in China and Europe and should this current certification work underway include in a timely and favorable manner, unlocking additional access to supply for customers looking for product. Given the timing of and development cycles of our Biorefining business, we again anticipate our revenue will be back half-weighted and the Q1 2024 revenue will look very much like Q1 2023. This suggests that we expect to see strong quarter-over-quarter growth throughout 2024 to reach our guidance range. We're highly confident in achieving our forecast. I'd like to highlight a couple of key drivers that could influence outcomes between the lower and upper end of our revenue guidance rate. First, as mentioned, the significant upside potential in the CarbonSmart business should certifications materialize quickly. Second, more favorable timing on FID and construction start for some projects in the pipeline would further benefit our performance in 2024. We believe this top-line performance, coupled with the efficiency and cost-focused actions we are taking, will further benefit our margins and profitability over the near and long term. Adjusted EBITDA loss for full year 2024 is expected to be $65 million to $55 million, reflecting the expected top-line growth range combined with our ongoing focus on high-quality margin opportunities and cost controls. Importantly, we're resetting the timing expectation for when we will achieve positive adjusted EBITDA. We previously expected this to occur in late 2024 with positive full year adjusted EBITDA in 2025. While we're encouraged by the strong growth we continue to see across the business in 2024, the delay of our expected return to profitability simply reflects our shifting view of specific project development timelines and not an erosion of our project pipeline. We are keenly focused on execution to achieve and accelerate our planned path to profitability and remain excited for the future of LanzaTech. Ending last year with more than $120 million in cash, restricted cash, cash equivalents and investments, we have significant financial flexibility and remain focused on maintaining this flexibility to ensure we're in the best position to achieve our growth objectives. Although we believe we have sufficient liquidity to execute on our near-term objectives, we will remain opportunistic around potential ways to supplement our flexibility, especially if it can accelerate our path to profitability and our growth over the long term. With that, I'll turn the call back over to Jennifer for some closing remarks before we open the call for Q&A. Jennifer?